{"product_id":"fulgentgenetics-business-model-canvas","title":"Fulgent Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Business Model Canvas: strategic playbook for investors, founders, and advisors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Fulgent’s strategic playbook with the full Business Model Canvas—detailing value propositions, customer segments, key partners, revenue streams, and cost drivers. Ideal for investors, consultants, and founders, this editable Word\/Excel file turns research into actionable strategy; download now to benchmark, plan, and scale with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and health system alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with hospitals and health systems secure steady sample inflows and enable integrated care pathways by embedding Fulgent workflows into clinical order and reporting systems. Embedded lab workflows reduce friction for ordering and accelerate result delivery to electronic health records. Co-development of testing protocols ensures alignment with clinical standards, while joint outcome studies support reimbursement and inclusion in clinical guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with academic and research institutions supply assay innovation and validation cohorts, giving Fulgent access to rare disease populations across roughly 7,000 known rare conditions, ~80% of which are genetic. Peer‑reviewed publications from these collaborations boost clinical adoption, while grant‑backed studies (NIH FY2024 appropriation ~50 billion) lower R\u0026amp;D risk and cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSequencing and technology vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRelationships with leading NGS platform providers (Illumina holds roughly 70% of the short‑read market) secure cutting‑edge instruments and volume pricing for Fulgent. Co‑optimization of assays and workflows measurably improves accuracy, throughput and TAT across high‑volume pipelines. Joint roadmaps with vendors ensure scalability and reliability while preferred support agreements minimize instrument downtime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech for companion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-development with pharma and biotech links Fulgent's tests to targeted therapies, enabling joint submission pathways and co-marketing with drug launches.\u003c\/p\u003e\n\u003cp\u003eBiomarker discovery and validation partnerships expand Fulgent's test menus and support regulatory-grade evidence generation for new indications.\u003c\/p\u003e\n\u003cp\u003eCompanion diagnostic approvals open new clinical markets and payer pathways, while sponsored testing programs accelerate oncologist adoption and real-world uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development: therapy alignment\u003c\/li\u003e\n\u003cli\u003eBiomarkers: menu expansion\u003c\/li\u003e\n\u003cli\u003eCDx approvals: market access\u003c\/li\u003e\n\u003cli\u003eSponsored testing: faster clinician adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and healthcare networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContracts with payers and networks secure coverage and predictable reimbursement, expanding patient access for Fulgent's genomic tests.\u003c\/p\u003e\n\u003cp\u003eData sharing aligns medical policies by integrating real-world evidence into payer guidelines, while value dossiers quantify clinical and economic benefits for coverage decisions.\u003c\/p\u003e\n\u003cp\u003eStreamlined prior authorization workflows reduce approval time and accelerate ordering and test utilization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003eMedical policy alignment\u003c\/li\u003e\n\u003cli\u003eValue dossiers: clinical + economic\u003c\/li\u003e\n\u003cli\u003eFaster prior authorization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital EHR integrations secure samples; academic assays cover \u003cstrong\u003e7,000\u003c\/strong\u003e rare diseases (\u003cstrong\u003e80%\u003c\/strong\u003e genetic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital integrations embed Fulgent workflows into EHRs to secure steady sample inflows; academic partnerships supply assay validation across ~7,000 rare diseases, ~80% genetic; vendor ties with Illumina (roughly 70% short‑read market) secure instruments and volume pricing; payer contracts and value dossiers drive coverage and faster prior authorization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/research\u003c\/td\u003e\n\u003ctd\u003eRare disease coverage\u003c\/td\u003e\n\u003ctd\u003e~7,000 conditions; ~80% genetic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS vendors\u003c\/td\u003e\n\u003ctd\u003eMarket share (short‑read)\u003c\/td\u003e\n\u003ctd\u003eIllumina ~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal R\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003eNIH appropriation FY2024\u003c\/td\u003e\n\u003ctd\u003e~$50 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Fulgent’s strategy, organized into the 9 classic BMC blocks with full narrative, insights, and competitive advantage analysis. Ideal for presentations, funding discussions, and decision-making, it links SWOT findings to each block and supports validation using real company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Fulgent that condenses strategy into a one-page snapshot, saving hours on formatting and enabling teams to quickly identify core components and adapt the model for boards, comparisons, or fast deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssay development and validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning targeted panels for rare disease, oncology, reproductive and infectious use cases, Fulgent prioritizes breadth and clinical relevance while leveraging sequencing costs near USD 600–1,000 per genome (2024) to optimize economics. Analytical and clinical validation follows CLIA, CAP and FDA-aligned standards with performance targets typically exceeding 99% sensitivity for SNVs and high reproducibility. Continuous iteration adds new genes and biomarkers quarterly to capture emerging evidence. Detailed validation dossiers and health‑economic documentation support payer coverage and guideline inclusion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-throughput sequencing operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-throughput sequencing operations at Fulgent cover sample accessioning, automated extraction, library prep, and multiplexed NGS runs to support clinical panels and large-scale screens. Automation drives scale and consistency, enabling throughput reported in 2024 alongside corporate revenue of $486.5 million. Rigorous QC protocols aim to keep reruns minimal and TAT optimized to meet clinical turnaround targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and interpretation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Fulgent operates proprietary pipelines for variant calling, annotation, and classification that feed a curated clinical knowledgebase to improve actionability. The team continuously curates evidence and reclassifies variants to reduce uncertain findings and increase diagnostic yield. Clinician-facing reports translate complex results into clear, actionable insights. A rules engine and models are regularly updated to reflect new guidelines and literature.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and data security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent maintains CLIA\/CAP accreditation with mandatory ongoing proficiency testing, strict SOP governance and continuous audit readiness; labs use documented change control and quarterly internal audits. Data protection aligns with HIPAA and GDPR standards through encryption, access controls and incident response; risk management includes formalized post-market surveillance and CAPA workflows to address quality or safety signals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCLIA\/CAP: ongoing proficiency testing, audit readiness\u003c\/li\u003e\n\u003cli\u003eSOP governance: version control, internal audits\u003c\/li\u003e\n\u003cli\u003eData security: HIPAA\/GDPR-aligned encryption \u0026amp; IR\u003c\/li\u003e\n\u003cli\u003eRisk \u0026amp; post-market: surveillance, CAPA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial enablement and provider education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOnboarding clinicians and health systems via streamlined workflows and EMR-integrated ordering increases test adoption; medical affairs drive KOL engagement to validate clinical utility and influence guidelines. Dedicated coding, billing and reimbursement support reduces denials and accelerates payment cycles. Robust digital tools and developer-facing APIs enable seamless ordering, reporting and EHR integration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnboarding: clinician and system integration\u003c\/li\u003e\n\u003cli\u003eMedical affairs: KOL development\u003c\/li\u003e\n\u003cli\u003eBilling: coding \u0026amp; reimbursement support\u003c\/li\u003e\n\u003cli\u003eDigital: APIs \u0026amp; EHR integrations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically focused NGS panels — \u003cstrong\u003e\u0026gt;99%\u003c\/strong\u003e SNV sensitivity, optimized TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent designs clinically focused NGS panels (rare disease, oncology, infectious) leveraging genome costs ~USD 600–1,000 (2024) to balance breadth and margins; validations follow CLIA\/CAP\/FDA-aligned standards with \u0026gt;99% SNV sensitivity and quarterly panel updates. High-throughput automated labs support 2024 revenue USD 486.5M and optimized TAT; pipelines, QC, and payer support drive adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eUSD 486.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenome cost\u003c\/td\u003e\n\u003ctd\u003eUSD 600–1,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSNV sensitivity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Fulgent Business Model Canvas you’re previewing is the exact document you’ll receive after purchase; it’s not a mockup or sample. When you buy, you’ll get this same fully formatted, ready-to-edit file in Word and Excel formats. No surprises—what you see is the final deliverable, complete and downloadable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA\/CAP-certified laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCLIA and CAP accreditation—with roughly 260,000 CLIA-certified U.S. laboratory entities and about 8,000 CAP-accredited programs globally—underpin clinical credibility for Fulgent. Redundant facility capacity enables surge response. High-throughput instrumentation and automation (eg, Illumina NovaSeq 6000 platforms delivering up to ~20 billion reads per run) drive daily throughput. Rigorous environmental controls and validated temperature\/humidity monitoring preserve sample integrity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary bioinformatics platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary bioinformatics platform runs optimized algorithms for alignment, variant calling and CNV detection, feeding an interpretation rules engine backed by curated databases updated weekly (2024). Scalable cloud architecture delivers rapid compute at ≥1,000 samples\/day with 99.95% availability, sub‑hour median pipeline runtime, and APIs for integration and reporting with \u0026lt;200 ms median latency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic and phenotypic knowledgebase\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's genomic and phenotypic knowledgebase aggregates variant classifications and outcomes with evidence-linked therapies and guideline references (eg, NCCN, FDA labeling) to differentiate reports with actionable clinical context; continuous curation through 2024 refines sensitivity and specificity, improving interpretation and therapy matching for clinicians and labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkilled multidisciplinary team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent leverages a skilled multidisciplinary team—molecular scientists, bioinformaticians, clinicians, and genetic counselors—integrated with regulatory, quality, and security experts plus field-based medical and commercial teams to support diagnostics and translational programs for trials and partnerships; the company operates as a NASDAQ-listed clinical genomics provider.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMolecular scientists\u003c\/li\u003e\n\u003cli\u003eBioinformaticians\u003c\/li\u003e\n\u003cli\u003eClinicians \u0026amp; genetic counselors\u003c\/li\u003e\n\u003cli\u003eRegulatory, quality \u0026amp; security experts\u003c\/li\u003e\n\u003cli\u003eField medical\/commercial teams\u003c\/li\u003e\n\u003cli\u003eProgram managers for partnerships\/trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer contracts and provider network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn-network status increases test volume and patient affordability while contracted rates smooth reimbursement timing; in 2024 Medicare enrollment reached about 66 million, reinforcing payer-driven demand. Established payer relationships cut prior-authorization and billing friction, and explicit coverage policies broaden clinical access to genomic and infectious-disease panels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-network = higher volume, lower OOP\u003c\/li\u003e\n\u003cli\u003eContracts = predictable revenue\u003c\/li\u003e\n\u003cli\u003eRelationships = reduced admin burden\u003c\/li\u003e\n\u003cli\u003eCoverage policies = expanded access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical sequencing: \u003cstrong\u003e20B\u003c\/strong\u003e reads\/run, 1,000+\/day, 99.95% uptime, 66M Medicare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCLIA (~260,000 U.S. labs) and CAP (~8,000 programs) accreditation, redundant facilities and NovaSeq platforms (~20B reads\/run) enable high-throughput, surge-capable testing. Proprietary bioinformatics and cloud pipelines process ≥1,000 samples\/day with 99.95% availability and sub‑hour median runtime. Curated knowledgebase, multidisciplinary staff and in‑network payer relationships (Medicare ~66M enrollees) support clinical adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccreditation\u003c\/td\u003e\n\u003ctd\u003eCLIA 260,000; CAP 8,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencing\u003c\/td\u003e\n\u003ctd\u003eNovaSeq ~20B reads\/run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e≥1,000 samples\/day; 99.95% avail; \u0026lt;1h median\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eMedicare ~66M enrollees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically actionable results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClear, guideline-aligned reports (ACMG standards) deliver treatment-informed results and therapy-matching where applicable; genomic testing yields up to ~40% diagnostic rates and can shorten the typical 4–7 year diagnostic odyssey, enabling risk stratification, targeted therapy options and measurable gains in patient outcomes and clinician confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad, modular test menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroad, modular test menu covers panels for rare disease, oncology, reproductive health and infectious diseases, enabling clinicians to consolidate testing. Customizable content supports institution-specific protocols and EMR workflows. Reflex testing options reduce turnaround and streamline care pathways. A future-ready R\u0026amp;D pipeline integrates emerging biomarkers to keep the menu clinically current.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh accuracy and fast turnaround\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValidated analytical sensitivity and specificity exceed 99% with CLIA-grade QC and external proficiency testing; automation and optimized workflows cut turnaround time by up to 72 hours versus manual processes; reliable scheduling guarantees STAT handling within 24 hours for time-critical cases; low rerun rates under 1% minimize downstream delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-effective and payer-aligned\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompetitive pricing and transparent billing simplify payer reconciliation and lower per-test administrative overhead.\u003c\/p\u003e\n\u003cp\u003eDedicated prior authorization and utilization management support speeds approvals and aligns testing with payer workflows.\u003c\/p\u003e\n\u003cp\u003eRobust evidence dossiers prove medical necessity and enable targeted interventions that lower avoidable downstream costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetitive pricing\u003c\/li\u003e\n\u003cli\u003eTransparent billing\u003c\/li\u003e\n\u003cli\u003ePrior auth support\u003c\/li\u003e\n\u003cli\u003eUtilization management\u003c\/li\u003e\n\u003cli\u003eEvidence dossiers for medical necessity\u003c\/li\u003e\n\u003cli\u003eReduces total cost of care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecure, integrated digital experience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSecure, integrated digital experience with FHIR\/HL7 EHR and API connectivity for ordering and results delivers structured, machine-readable data and HIPAA-compliant audit trails that meet regulatory requirements.\u003c\/p\u003e\n\u003cp\u003eStructured results enable faster interpretation and decisioning, cutting provider documentation burden by about 30% while enterprise-grade uptime (99.9% SLA) ensures reliable access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFHIR\/HL7 APIs\u003c\/li\u003e\n\u003cli\u003eHIPAA audit trails\u003c\/li\u003e\n\u003cli\u003eStructured, machine-readable results\u003c\/li\u003e\n\u003cli\u003e~30% reduced provider burden\u003c\/li\u003e\n\u003cli\u003e99.9% SLA uptime\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACMG-aligned reports with therapy-matching and \u003cstrong\u003e~40%\u003c\/strong\u003e diagnostic yield\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClear ACMG-aligned reports with therapy-matching and ~40% diagnostic yield shorten the 4–7 year diagnostic odyssey; \u0026gt;99% analytic sensitivity\/specificity and \u0026lt;1% rerun rates ensure reliability; automation cuts TAT by up to 72 hours and STAT handling in 24 hours; FHIR\/HL7 APIs reduce provider burden ~30% with 99.9% uptime.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic yield\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003ctd\u003eFaster diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensitivity\/Specificity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003ctd\u003eClinical confidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAT improvement\u003c\/td\u003e\n\u003ctd\u003e−72 hrs\u003c\/td\u003e\n\u003ctd\u003eFaster care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider burden\u003c\/td\u003e\n\u003ctd\u003e−30%\u003c\/td\u003e\n\u003ctd\u003eEfficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUptime\u003c\/td\u003e\n\u003ctd\u003e99.9% SLA\u003c\/td\u003e\n\u003ctd\u003eAccess\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNamed reps guide onboarding and partner with clients to drive site-level growth, aligning milestones with operational capacity.\u003c\/p\u003e\n\u003cp\u003eQuarterly business reviews and KPI tracking are used to optimize service delivery and adapt workflows to evolving needs.\u003c\/p\u003e\n\u003cp\u003eRapid escalation paths ensure priority issue resolution, while account teams design tailored solutions for each site’s workflow and compliance requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical support and genetic counseling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical support and genetic counseling provide access to experts for case review and result interpretation, with pre- and post-test counseling where applicable to ensure appropriate test selection and follow-up. Educational resources and regular office hours bolster clinician confidence and patient trust, reducing misorders. This approach aligns with a global genetic testing market near USD 18 billion in 2024 and drives higher-quality utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelf-serve digital portal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSelf-serve digital portal provides real-time order tracking and status updates, easy retrieval of reports and prior results, and embedded decision support tools to guide clinicians; 2024 studies show self-service channels cut support contacts by about 30–40%, reducing phone and email dependency while improving turnaround visibility and clinician workflow efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical education and KOL engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedical education and KOL engagement delivered via grand rounds, webinars and accredited CME content reinforce Fulgent's clinical value proposition and leverage its CLIA-certified labs and genomic services; Fulgent is Nasdaq-listed as FLGT in 2024.\u003c\/p\u003e\n\u003cp\u003eRegular evidence sharing from peer-reviewed studies and internal registries informs prescriber decisions and supports guideline-consistent usage across oncology and rare disease pathways.\u003c\/p\u003e\n\u003cp\u003ePeer-to-peer forums and case conferences enable escalation of complex cases to KOLs, increasing appropriate test utilization and uptake of recommended workflows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrand rounds, webinars, CME\u003c\/li\u003e\n\u003cli\u003eEvidence from studies and registries\u003c\/li\u003e\n\u003cli\u003ePeer-to-peer complex-case forums\u003c\/li\u003e\n\u003cli\u003eDrives guideline-consistent usage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive billing and reimbursement help\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResponsive billing and reimbursement help delivers coding guidance and documentation templates, patient financial counseling with flexible payment options, and proactive denial management that shortens revenue cycles and reduces provider admin; industry data shows average claim denial rates near 9% in 2024 and median days in AR ~45, highlighting RCM impact on cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoding templates and guidance\u003c\/li\u003e\n\u003cli\u003ePatient counseling \u0026amp; payment plans\u003c\/li\u003e\n\u003cli\u003eProactive denial management\u003c\/li\u003e\n\u003cli\u003eReduces denials (~9% industry avg 2024) and shortens days in AR (~45)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReps + portal reduce support 30-40%, drive guideline use in $18B oncology market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNamed reps + portal blend proactive onboarding, KPIs, and rapid escalation to improve site workflows and reduce support loads 30–40% via self-service.\u003c\/p\u003e\n\u003cp\u003eClinical KOLs, genetic counseling, CME and evidence-sharing drive guideline-consistent use across oncology and rare disease (market ~$18B in 2024).\u003c\/p\u003e\n\u003cp\u003eResponsive RCM with coding templates and denial management targets ~9% industry denials and ~45 days AR to accelerate cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics market\u003c\/td\u003e\n\u003ctd\u003e$18B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport reduction\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaim denials\u003c\/td\u003e\n\u003ctd\u003e~9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDays in AR\u003c\/td\u003e\n\u003ctd\u003e~45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField reps engage hospitals, clinics and labs—targeting about 6,100 US hospitals and thousands of outpatient sites—to build institutional relationships. Demos and pilots (short-term lab validations) lower clinical adoption barriers and provide operational proof points. Contracting aligns volume tiers and pricing to secure predictable revenue streams. Ongoing technical and account support sustains utilization and expands test mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital portal and APIs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital portal with online ordering and result delivery plus APIs for EHR\/LIS integrations reduces manual steps and enables automated notifications that improve visibility and turnaround. Fulgent serves all 50 states and trades on NASDAQ: FLGT, supporting scalable national operations without heavy field presence. The platform handles high-volume testing workflows while pushing results and orders into EHRs\/LIS in real time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth system and IDN integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmbedded order sets and care pathways integrated into EHR workflows drive clinical adoption and streamlined ordering; Fulgent reported processing over 1 million tests annually by 2024, enabling standardized protocols across sites. Enterprise agreements standardize usage and pricing, reducing administrative friction and supporting bulk contracting. Robust data exchange feeds population-health analytics, and multi-site rollouts accelerate volume growth and per-site utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChannel partners and distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegional labs and service providers extend Fulgent’s reach into underserved markets, with the molecular diagnostics market estimated at ~$14B in 2024 supporting scalable demand. Co-branded offerings close coverage gaps while logistics partners streamline sample transport, improving turnaround and reliability. These channels reduce customer acquisition cost in new geographies by concentrating local trust and infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegional labs: extend reach\u003c\/li\u003e\n\u003cli\u003eCo-branded: fills gaps\u003c\/li\u003e\n\u003cli\u003eLogistics: faster transport\u003c\/li\u003e\n\u003cli\u003eLower CAC: faster entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConferences and professional societies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent maintains a visible presence at oncology, clinical genetics, and obstetrics meetings, using abstracts and sponsored symposia to demonstrate assay performance and clinical utility.\u003c\/p\u003e\n\u003cp\u003eThese activities drive networking that seeds partnerships, investigator-initiated and industry trials, and supports awareness and demand generation among clinicians and labs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: oncology, genetics, obstetrics meetings\u003c\/li\u003e\n\u003cli\u003eMechanisms: abstracts, symposia, posters\u003c\/li\u003e\n\u003cli\u003eOutcomes: partnerships, trial leads, referral demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField reps and digital APIs drive adoption across ~6,100 hospitals, \u0026gt;1M tests, $14B market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eField reps, demos\/pilots and enterprise contracting drive institutional adoption across ~6,100 US hospitals and thousands of outpatient sites, supporting \u0026gt;1M tests processed annually by 2024. Digital portal + APIs enable EHR\/LIS integration and national scaling (serves all 50 states; NASDAQ: FLGT). Regional labs, co-brands and logistics lower CAC and expand rural reach in a ~$14B molecular diagnostics market (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eReach\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003eHospitals\/clinics\u003c\/td\u003e\n\u003ctd\u003e~6,100 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/API\u003c\/td\u003e\n\u003ctd\u003eNationwide\u003c\/td\u003e\n\u003ctd\u003eAll 50 states; \u0026gt;1M tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional partners\u003c\/td\u003e\n\u003ctd\u003eUnderserved markets\u003c\/td\u003e\n\u003ctd\u003e$14B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologists and cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists and cancer centers require biomarker-driven treatment guidance where tumor and germline testing inform therapy selection and hereditary risk management; rapid turnaround time (clinically, under 7 days when possible) directly alters regimen decisions. CDx alignment is critical—as of 2024 the FDA has authorized more than 50 companion diagnostics, driving adoption and reimbursement discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneticists, neurologists and pediatricians seek definitive diagnoses for rare disease patients, where the diagnostic odyssey averages 5–7 years. Exome and targeted panel testing deliver diagnostic yields of roughly 25–40% and significantly shorten time to diagnosis versus serial testing. Trio analysis and phenotype-driven interpretation can boost yield by about 10–15% while clinical phenotype tools prioritize variants. Long-term follow-up data informs prognosis and can alter management in up to 60% of diagnosed cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReproductive health providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOB\/GYNs and fertility clinics rely on carrier screening, NIPT, and PGT as adjunct tests to guide reproductive decision-making. NIPT offers about 99% detection for trisomy 21; clear reports and counseling directly support patient decisions. Turnaround time (commonly 5–7 business days) and high accuracy affect pregnancy management, and insurance alignment materially improves access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health and infectious disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic health and infectious disease programs rely on Fulgent for surveillance and diagnostic testing at scale, with rapid deployment capability during outbreaks and integrated data feeds that support epidemiology and resource planning; contract-based volumes provide predictable baseline demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSurveillance testing scale\u003c\/li\u003e\n\u003cli\u003eRapid outbreak deployment\u003c\/li\u003e\n\u003cli\u003eData feeds for epidemiology\u003c\/li\u003e\n\u003cli\u003eContract-stabilized volumes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech sponsors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent serves pharma and biotech sponsors with CDx development, clinical trial testing, and biomarker research via CLIA\/CAP central lab services that emphasize strict quality and chain-of-custody controls; global scalability and regulatory support accelerate submissions and approvals with integrated data packages.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCLIA\/CAP certified (2024)\u003c\/li\u003e\n\u003cli\u003eGlobal reach: 100+ countries (2024)\u003c\/li\u003e\n\u003cli\u003eCentral lab for trials and CDx\u003c\/li\u003e\n\u003cli\u003eRegulatory-ready data packages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker testing: \u003cstrong\u003e50+\u003c\/strong\u003e CDx, rapid TAT under 7d, \u003cstrong\u003e99%\u003c\/strong\u003e NIPT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncologists\/cancer centers: biomarker-driven testing with CDx alignment (50+ FDA companion diagnostics in 2024), rapid TAT (\u0026lt;7 days) impacting therapy choices.\u003c\/p\u003e\n\u003cp\u003eGenetics\/neurology: rare-disease exome\/panels yield ~25–40% (trio +10–15%), shortens 5–7yr diagnostic odysseys and alters management in ~60% of cases.\u003c\/p\u003e\n\u003cp\u003eRepro\/PH\/pharma: NIPT ~99% T21 detection, PGT\/carrier screening and CLIA\/CAP central lab services (2024) with global reach 100+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metrics (2024)\u003c\/th\u003e\n\u003cth\u003eTAT\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e50+ CDx\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;7d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003e25–40% yield\u003c\/td\u003e\n\u003ctd\u003eweeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepro\/PH\/Pharma\u003c\/td\u003e\n\u003ctd\u003e99% NIPT; 100+ countries\u003c\/td\u003e\n\u003ctd\u003e5–7d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagents and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReagents and consumables—nucleic acids extraction kits, library prep reagents, sequencing flow cells and disposables—represent the largest variable COGS line for Fulgent, with volume-based supplier pricing and contract tiers directly driving per-sample margins. Rigorous inventory management (just-in-time ordering, automated reorder points) prevents costly stockouts and rush freight. Structured waste-reduction and reuse programs lower disposal and repurchase frequency, tightening COGS and stabilizing unit economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor and staffing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLabor and staffing costs cover ASCP-credentialed lab technologists, molecular scientists, genetic counselors, and bioengineers plus field and customer-support teams to sustain service delivery. Continuous training and retention programs reduce diagnostic error rates and protect CLIA\/CAP compliance. 24\/7 shift coverage and scalable staffing models ensure throughput for high-volume sequencing and reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical validation require assay design ($200k–1M) and software development ($500k–3M) plus studies costing $0.5–5M per pivotal program (2024 industry averages). Sample acquisition runs $20–200 per sample with external collaborations often $100k–2M. Regulatory submissions and documentation typically cost $250k–1.5M, with continuous pipeline improvement consuming ~10–15% of R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud, IT, and cybersecurity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCloud compute, storage and egress drive material variable costs: AWS S3 Standard ~0.023 USD\/GB-month and data egress ~0.09 USD\/GB (first 10 TB) in 2024, with GPU\/CPU pipeline hours adding significant compute spend.\u003c\/p\u003e\n\u003cp\u003eLIMS and integration maintenance typically run ~15–20% of annual license value in 2024, plus ongoing ETL and API upkeep.\u003c\/p\u003e\n\u003cp\u003eSecurity tooling, quarterly audits, and formal uptime\/disaster recovery SLAs (99.9–99.99%) add fixed ops and contingency reserves.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud storage: 0.023 USD\/GB-month\u003c\/li\u003e\n\u003cli\u003eData egress: 0.09 USD\/GB (first 10 TB)\u003c\/li\u003e\n\u003cli\u003eLIMS maintenance: ~15–20% annual\u003c\/li\u003e\n\u003cli\u003eUptime SLA: 99.9–99.99%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory, quality, and compliance costs for Fulgent center on maintaining CLIA\/CAP accreditations, recurring proficiency testing and third-party audits, continuous SOP management and staff training, comprehensive legal and HIPAA privacy programs, plus insurance and enterprise risk management to cover liability and cyber risks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccreditations: CLIA\/CAP maintenance\u003c\/li\u003e\n\u003cli\u003eProficiency testing \u0026amp; audits: ongoing external programs\u003c\/li\u003e\n\u003cli\u003eSOPs \u0026amp; training: continuous staff certification\u003c\/li\u003e\n\u003cli\u003eLegal\/privacy: HIPAA, breach preparedness\u003c\/li\u003e\n\u003cli\u003eInsurance: liability, cyber, business continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagents and lab labor drive unit economics; JIT inventory and retention cut per-sample cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReagents\/consumables (largest variable COGS) and lab labor (ASCP technologists, counselors) drive unit economics; JIT inventory and retention lower per-sample cost. R\u0026amp;D\/validation programs average $0.5–5M per program (2024), cloud storage $0.023 USD\/GB-month and egress $0.09\/GB. LIMS maintenance ~15–20% annually; uptime SLAs 99.9–99.99% add fixed ops.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Line\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\/consumables\u003c\/td\u003e\n\u003ctd\u003eVolume-priced per-sample\u003c\/td\u003e\n\u003ctd\u003eLargest variable COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab labor\u003c\/td\u003e\n\u003ctd\u003eASCP staff, 24\/7 shifts\u003c\/td\u003e\n\u003ctd\u003eHigh fixed\/variable mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/validation\u003c\/td\u003e\n\u003ctd\u003e$0.5–5M\/program\u003c\/td\u003e\n\u003ctd\u003eCapitalized pipeline cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003e$0.023\/GB-mo; $0.09\/GB egress\u003c\/td\u003e\n\u003ctd\u003eScalable variable cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLIMS maintenance\u003c\/td\u003e\n\u003ctd\u003e15–20% annual\u003c\/td\u003e\n\u003ctd\u003eRecurring ops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLAs \u0026amp; security\u003c\/td\u003e\n\u003ctd\u003e99.9–99.99% uptime\u003c\/td\u003e\n\u003ctd\u003eContingency reserves\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical test reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayments come from commercial insurers and government programs, with in-network contracting driving predictable cash flows through agreed fee schedules. Prior authorization support increases approval rates for high-cost tests, reducing write-offs. Active denial management and resubmission workflows protect revenue yield and shorten days receivable. Integration with payer portals improves collection efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelf-pay and patient-paid testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent’s self-pay and patient-paid testing emphasizes transparent pricing for uninsured or non-covered tests, with clear price lists and eligibility checks; payment plans and targeted discounts are offered to improve affordability. Direct-to-patient programs are used where regulation permits, and this channel helps reach the roughly 8–9% of U.S. residents who lack insurance, expanding access beyond payer limits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnterprise and health system contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnterprise and health system contracts use volume-based pricing with tiered discounts of 10–35% and bundled services; integration fees typically range from $50k–$500k with support packages $5k–$50k\/month. SLA-backed arrangements guarantee TAT of 24–72 hours and quality metrics, and multi-year terms (3–5 years) stabilize recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharma and biotech services generate milestone and royalty income from CDx co-development deals (royalties commonly structured as mid-single to low-double digits), steady clinical testing fees and sample logistics for trials, biomarker discovery and bioinformatics service contracts, and growing post-approval companion testing volumes as uptake of targeted therapies increases; over 70 FDA-authorized companion diagnostics existed by 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDx milestones + royalties: structured mid-single to low-double digit rates\u003c\/li\u003e\n\u003cli\u003eClinical trial testing: per-trial service and sample logistics revenue\u003c\/li\u003e\n\u003cli\u003eBiomarker discovery: fee-for-service + data licensing\u003c\/li\u003e\n\u003cli\u003ePost-approval: volume-driven companion test revenue (growing adoption)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic sector and population programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic-sector and population programs drive Fulgent revenue via government contracts for screening and outbreak response, grants supporting research and pilot deployments, and fixed-fee or per-test pricing models with data reporting services under compliance; US population ~334 million (2023 Census) shapes scale and demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment contracts: outbreak screening\u003c\/li\u003e\n\u003cli\u003eGrants: research\/pilots\u003c\/li\u003e\n\u003cli\u003ePricing: fixed-fee or per-test\u003c\/li\u003e\n\u003cli\u003eServices: compliant data reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDx revenue splits: payer fees, self-pay \u003cstrong\u003e8-9%\u003c\/strong\u003e, \u003cstrong\u003e70\u003c\/strong\u003e FDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue derives from payer fee-schedules and denial management, direct-to-patient self-pay (~8–9% uninsured), enterprise contracts with 10–35% volume discounts, pharma CDx milestones\/royalties (mid-single to low-double digits) and government fixed-fee\/per-test programs; 70 FDA-authorized companion diagnostics existed by 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eTypical Rate\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnterprise\u003c\/td\u003e\n\u003ctd\u003eIntegration $50k–$500k\u003c\/td\u003e\n\u003ctd\u003e10–35% discounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma CDx\u003c\/td\u003e\n\u003ctd\u003e70 FDA CDx\u003c\/td\u003e\n\u003ctd\u003eMid-single–low-double %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098001707356,"sku":"fulgentgenetics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/fulgentgenetics-business-model-canvas.png?v=1781794895","url":"https:\/\/pestel-analysis.com\/products\/fulgentgenetics-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}